Urea Cycle Disorders

Ammonia Detoxification Pathway and Enzymatic Block

• Hyperammonemia as Primary Neurotoxin: Ammonia crosses the blood-brain barrier via aquaporin-9 (AQP9) transporters and impairs glutamate neurotransmission through multiple mechanisms. In astrocytes, ammonia is incorporated into glutamine via glutamine synthetase, depleting glutamate (the primary excitatory neurotransmitter) and glutamine (an osmolyte and nitrogen carrier). Ammonia also inhibits α-ketoglutarate dehydrogenase, impairing oxidative metabolism and ATP production in neurons. Excess ammonia drives conversion of α-ketoglutarate to glutamate, further depleting the Krebs cycle and causing energy failure. The resulting reduced GABAergic inhibition, impaired neurotransmission, and mitochondrial dysfunction create a state of neuronal hyperexcitability progressing to cerebral edema, seizures, and coma. Ammonia levels >200 μmol/L correlate with severe encephalopathy; levels >500 μmol/L are associated with coma and permanent brain damage if untreated.

• Secondary Metabolic Dysfunction and Amino Acid Abnormalities: Enzyme deficiency also prevents synthesis of downstream urea cycle intermediates, particularly citrulline and arginine, which are conditionally essential amino acids in UCDs. Arginine deficiency impairs nitric oxide synthesis and immune function; citrulline deficiency contributes to metabolic dysfunction. Simultaneously, upstream substrate accumulation creates characteristic amino acid patterns: in OTC deficiency, carbamoyl phosphate accumulates and diverts into pyrimidine synthesis pathways, causing secondary orotic aciduria (massive urinary excretion of orotic acid), a pathognomonic finding. Different enzyme deficiencies produce distinct metabolite profiles (plasma and urine amino acid ratios, orotic acid, citrulline, etc.) useful for specific diagnosis.

• Precipitants of Acute Decompensation: Although genetic mutations are permanent, acute hyperammonemic crises occur episodically, triggered by conditions that increase ammonia generation or stress hepatic function: infections (URI, UTI, viral illness), high protein intake, fasting/catabolism, surgery/trauma, and certain medications (valproate, salicylates, corticosteroids). These precipitants increase amino acid catabolism, overwhelm the already-compromised urea cycle's capacity, and cause ammonia to spike rapidly, precipitating encephalopathy within hours. This explains the variable clinical presentation—some patients with severe genotypes remain asymptomatic until hit by a major precipitant, while others manifest in the neonatal period.

• Cerebral Edema and Increased Intracranial Pressure: In severe hyperammonemia (>200-300 μmol/L), astrocytic swelling occurs via ammonia-induced osmotic imbalance and impaired aquaporin-4 function, leading to cerebral edema and raised intracranial pressure (ICP). Seizures result from ammonia-induced neuronal hyperexcitability and GABAergic dysfunction. Unchecked increases in ICP cause brainstem herniation, apnea, and death.

• OTC Deficiency (X-linked, ~50% of all UCDs): Caused by mutations in the OTC gene on Xp21.1, encoding the second enzyme in the urea cycle. Males are more severely affected (hemizygous); heterozygous females may be asymptomatic or mildly symptomatic depending on X-inactivation patterns. OTC deficiency causes accumulation of carbamoyl phosphate and ammonia with normal or low citrulline levels, distinguishing it biochemically from other defects.

• Carbamoyl Phosphate Synthetase I Deficiency (Autosomal Recessive): Caused by mutations in the CPS1 gene; the first and rate-limiting enzyme of the cycle. Presents similarly to OTC deficiency with severe neonatal hyperammonemia but with markedly elevated carbamoyl phosphate levels and orotic aciduria (like OTC) or normal/low orotic acid (distinguishing feature). Often the most severe form with high neonatal mortality if untreated.

• Argininosuccinate Synthetase Deficiency (Citrullinemia Type I, Autosomal Recessive): Mutations in ASS1 gene cause citrulline accumulation in plasma and urine (>1000 μmol/L, pathognomonic). Presents with neonatal hyperammonemia and characteristic markedly elevated citrulline.

• Argininosuccinate Lyase Deficiency (Autosomal Recessive): Causes argininosuccinic aciduria (massive urinary crystalline argininosuccinate) with variable hyperammonemia. Patients may have developmental delay, liver dysfunction, or remain asymptomatic despite enzyme deficiency.

• Arginase Deficiency (Autosomal Recessive, Rarest): Mutations in ARG1 gene; most patients remain asymptomatic or present with mild hyperammonemia, developmental delay, and spasticity (neurological presentation more prominent than metabolic). Plasma and urine arginine markedly elevated.

• N-Acetylglutamate Synthase (NAGS) Deficiency (Autosomal Recessive, Extremely Rare): NAGS synthesizes N-acetylglutamate (NAG), an allosteric activator essential for CPS1 function. Deficiency causes severe neonatal hyperammonemia and is the only UCD treatable with NAG supplementation alone (without protein restriction).

• Secondary/Acquired Hyperammonemia (Non-Genetic Triggers): Advanced liver disease, portosystemic shunting, Reye syndrome, and certain drugs (valproate) can cause hyperammonemia in genetically normal individuals, but the underlying mechanism differs (hepatic synthesis impairment vs. enzymatic block).

Acute Hyperammonemic Encephalopathy (Classic Presentation)

• Neonatal Presentation (Most Common for Severe Genotypes): Symptoms begin within the first 24-72 hours of life (sometimes hours after birth) in OTC deficiency and CPS1 deficiency. Affected neonates present with poor feeding, vomiting, lethargy progressing to seizures and coma. Developmental regression occurs rapidly; untreated infants deteriorate to brainstem signs and death within days. The combination of a normal initial ammonia at birth (maternal clearance of ammonia in utero) followed by rapid rise as neonatal metabolism kicks in is characteristic.

• Late-Onset Presentation (Mild to Moderate Genotypes or Heterozygous Females): Presentation deferred to childhood, adolescence, or adulthood triggered by stress (infection, surgery, high-protein meal). Recurrent episodes of encephalopathy with variable severity; between episodes, patients may be neurologically normal or have subtle deficits (learning disability, attention problems, developmental delay). Some asymptomatic adults are diagnosed only after a relative presents with UCD, or incidentally during workup of hyperammonemia.

• Neurological Complications (Chronic Effects): Repetitive hyperammonemic episodes cause permanent brain injury manifesting as developmental delay, intellectual disability, spastic paraparesis, behavioral disorders, and growth retardation. Cerebral palsy-like syndrome (spasticity, dystonia) can develop. Patients often have characteristic speech abnormalities (dysarthria), gait disturbance, and learning disabilities. Imaging may show basal ganglia signal abnormalities (T2 hyperintensity in striatum), white matter disease, or cerebral atrophy.

• Hepatic Manifestations: While the primary defect is enzymatic, not hepatic, some UCDs have associated liver dysfunction. Hepatomegaly may develop, especially in CPS1 deficiency. Cirrhosis can occur in chronic disease. Argininosuccinate lyase deficiency particularly associated with progressive liver disease and failure.

Physical Exam Findings

• Altered Mental Status: Ranging from mild confusion/lethargy to deep coma; may progress over hours.

• Asterixis ("Flapping Tremor"): Characteristic of hepatic encephalopathy and ammonia-induced metabolic encephalopathy; not always present in very acute cases or deep coma.

• Seizure Activity: Generalized or subtle myoclonic jerks; may be refractory to standard anticonvulsants.

• Signs of Cerebral Edema: Pupil abnormalities (dilated, sluggish), posturing (decorticate or decerebrate), loss of brainstem reflexes (oculocephalic, corneal), apnea.

• Growth Retardation and Dysmorphia: Chronic disease causes failure to thrive, small stature.

• Spasticity and Hyperreflexia: From chronic ammonia-induced basal ganglia injury; may be present between acute episodes.

Clinical Suspicion and Historical Features

• Plasma Ammonia Level (Primary Diagnostic Test): Elevated fasting ammonia (>100 μmol/L; normal <50 μmol/L) is the hallmark of UCD. Levels >200 μmol/L correlate with encephalopathy; >500 μmol/L indicates severe disease with high mortality risk. Ammonia is unstable and must be drawn anaerobically on ice and transported immediately to lab; improper sampling falsely elevates values. Ammonia alone does not pinpoint which enzyme is deficient; the pattern of plasma amino acids does. Serial ammonia monitoring during acute crises guides treatment intensity.

• Plasma and Urine Amino Acid Analysis (Discriminatory Test): Each UCD produces a characteristic amino acid fingerprint that identifies the specific enzyme deficiency:
• OTC Deficiency: Elevated glutamine/glutamate ratio and elevated alanine (from hyperammonemia-driven transamination), LOW citrulline (can be normal or low), elevated ammonia. Orotic acid in urine markedly elevated (can exceed 1000 μmol/L; normal <2 μmol/L).
• CPS1 Deficiency: Similar pattern to OTC but with normal or low orotic acid (since carbamoyl phosphate doesn't accumulate as much).
• Argininosuccinate Synthetase Deficiency (Citrullinemia I): Massively elevated citrulline in plasma (often >1000 μmol/L; normal 10-50) and urine; this is pathognomonic.
• Argininosuccinate Lyase Deficiency: Elevated argininosuccinic acid in plasma and massive urinary crystalline argininosuccinate; variable hyperammonemia.
• Arginase Deficiency: Elevated plasma and urine arginine with mild hyperammonemia; often asymptomatic or neurological symptoms predominate.
• NAGS Deficiency: Low citrulline, elevated ammonia, but normal orotic acid (carbamoyl phosphate doesn't accumulate because CPS1 is the rate-limiting enzyme and is already inhibited by lack of NAG).

• Urine Orotic Acid Measurement: Markedly elevated in OTC and CPS1 deficiency (>1000 μmol/L vs. normal <2 μmol/L); normal or low in other UCDs, helping differentiate OTC/CPS1 from downstream defects. This simple urine test is a powerful discriminatory tool.

• Genetic Testing: DNA sequencing of UCD genes (OTC, CPS1, ASS1, ASL, ARG1, NAGS) confirms diagnosis and identifies mutations, important for genetic counseling and carrier identification. Increasingly available and should be pursued when suspicion is high.

• Liver Function Tests and Imaging: In most UCDs, liver function tests are normal (AST/ALT, bilirubin, synthetic function); this is a key distinguishing feature from liver disease. Abdominal ultrasound usually shows normal liver structure unless cirrhosis has developed (rare except in advanced argininosuccinate lyase deficiency). Normal LFTs in the setting of hyperammonemia and encephalopathy is a diagnostic clue pointing toward UCD rather than hepatic encephalopathy.

• Neuroimaging (MRI): During acute encephalopathy, cerebral edema may be visible as effacement of subarachnoid spaces, compressed ventricles, or brainstem compression. T2/FLAIR hyperintensities in the basal ganglia (particularly putamen) are characteristic of chronic ammonia-induced injury and appear in chronic disease or after recurrent episodes. White matter abnormalities and cerebral atrophy may develop over time.

• CSF Analysis: Usually normal (occasionally elevated protein from CNS irritation); performed to rule out infection/meningitis in encephalopathy workup but not diagnostic for UCD.

Diagnostic Criteria

• Confirmed UCD diagnosis requires: (1) hyperammonemia (ammonia >100 μmol/L) documented on ≥2 occasions (since

Immediate stabilisation (acute hyperammonemic crisis is a metabolic emergency)

• Stop all protein/nitrogen intake: halt enteral protein for 24–48 hours only — longer restriction provokes catabolism and paradoxically worsens ammonia.
• Reverse catabolism with high-rate IV dextrose (10% or higher) plus intravenous lipid emulsion, with insulin added for hyperglycemia: the goal is to push the patient into anabolism so endogenous protein is not broken down. Per the Urea Cycle Disorders Consensus Conference recommendations and the ACMG newborn-screening ACT sheets, this plus scavenger therapy is started before the specific enzyme defect is known.
• Neuroprotection: intubate the comatose patient; avoid hypotonic fluid and volume overload, which aggravate ammonia-driven astrocytic swelling.

First-line pharmacotherapy — alternative pathway (nitrogen scavenger) therapy

• IV sodium phenylacetate/sodium benzoate: benzoate conjugates glycine to hippurate; phenylacetate conjugates glutamine to phenylacetylglutamine. Both are renally excreted, disposing of waste nitrogen while bypassing the blocked cycle.
• IV arginine hydrochloride: regenerates ornithine so residual cycle activity distal to the block can run; in citrullinemia and argininosuccinic aciduria it permits nitrogen excretion as citrulline/argininosuccinate. Contraindicated in arginase deficiency.
• Carglumic acid: an N-acetylglutamate analogue that allosterically activates CPS1 — the targeted therapy for NAGS deficiency.

Escalation

• Hemodialysis is the fastest ammonia clearance and is indicated for coma, ammonia in the severe range (commonly cited around ≥500 μmol/L), or failure to fall on scavengers; continuous hemodiafiltration is used if hemodynamically unstable. Peritoneal dialysis and exchange transfusion clear ammonia too slowly.

Disease-related — emergencies

• Cerebral edema with raised ICP and herniation (emergency): ammonia-driven astrocytic glutamine accumulation acts as an intracellular osmole; signalled by pupillary abnormalities, posturing, bradycardia with hypertension, or apnea. Requires airway control and emergent ammonia clearance, not observation.
• Status epilepticus (emergency): glutamate/GABA imbalance plus energy failure; seizures may be subtle (myoclonus, eye deviation) and refractory until ammonia falls.
• Rebound hyperammonemia after stopping dialysis or resuming protein (emergency): signalled by re-emerging lethargy and vomiting; mandates serial ammonia monitoring rather than a single reassuring value.

Disease-related — chronic

• Permanent neurocognitive injury: cumulative duration and peak of hyperammonemia predict intellectual disability, ADHD-like behavior, and T2/FLAIR basal ganglia and white-matter signal change on MRI.
• Spastic diplegia: characteristic of arginase deficiency, where progressive spasticity dominates over ammonia crises.
• Hepatic fibrosis and hypertension: particularly in argininosuccinate lyase deficiency, attributed in part to impaired arginine-dependent nitric oxide synthesis.

Treatment-related

• Sodium and volume overload from IV phenylacetate/benzoate: each gram carries a substantial sodium load; signalled by hypernatremia, edema, or worsening cerebral edema.
• Hypokalemia and metabolic derangement with phenylacetate/phenylbutyrate: renal excretion of the conjugate drags potassium; check electrolytes with each ammonia level.
• Branched-chain and essential amino acid depletion: scavengers consume glutamine and glycine and protein restriction removes substrate — signalled by poor growth, low plasma BCAAs, brittle hair, and dermatitis (acrodermatitis-like rash is classic in arginine/protein deficiency).
• Phenylbutyrate intolerance: strong body odor, taste aversion, and nonadherence; amenorrhea has been reported.
• Central venous access and dialysis complications: catheter sepsis, hypotension, bleeding.
• Post-transplant immunosuppression risks: infection and malignancy; note that transplant does not normalize plasma amino acids in ASL deficiency.

• The metabolic triad that identifies a urea cycle disorder: hyperammonemia without metabolic acidosis, without ketosis, and with normal glucose — often accompanied by respiratory alkalosis because ammonia stimulates central hyperventilation. Organic acidemias give you a high anion-gap acidosis with ketosis and hypoglycemia; that single contrast resolves most stems.
• Single best next step in a hyperammonemic neonate: stop protein, start high-rate IV dextrose (± lipids/insulin) to abolish catabolism, and give a nitrogen scavenger — do not wait for the amino acid panel. Escalate to hemodialysis for coma or severely elevated/rising ammonia.
• Orotic acid is the discriminator: markedly elevated in OTC deficiency (carbamoyl phosphate spills into pyrimidine synthesis) and low/normal in CPS1 and NAGS deficiency, where carbamoyl phosphate is never made.
• The classic distractor: hereditary orotic aciduria (UMP synthase deficiency) also has orotic aciduria — but with megaloblastic anemia and NO hyperammonemia, and it is treated with uridine. OTC deficiency has hyperammonemia and no anemia.
• The association examiners love: valproic acid precipitating encephalopathy in an adolescent or adult female — think a heterozygous OTC carrier unmasked by an ureagenesis inhibitor (X-linked, variable severity by skewed X-inactivation).
• Citrulline direction tells you the level of the block: low in CPS1/OTC/NAGS, massively elevated in citrullinemia type I, elevated arginine in arginase deficiency.
• Timing buzzword: normal at birth (placenta cleared the ammonia), then vomiting, lethargy, and coma within 24–72 hours of protein feeding — mimics neonatal sepsis, so send an ammonia on any encephalopathic neonate.
• Two traps: normal LFTs and no jaundice argue against hepatic encephalopathy — lactulose/rifaximin are the wrong answer; and arginine, otherwise a mainstay, is contraindicated in arginase deficiency.
• Specimen handling matters: ammonia must be drawn free-flowing, kept on ice, and run immediately, or it is falsely high.